文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性抗VEGF治疗不依从与不坚持的定义

Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该研究通过系统综述和改良德尔菲法,由视网膜专家小组制定并验证了新生血管性年龄相关性黄斑变性(nAMD)患者抗血管内皮生长因子(VEGF)治疗不依从与不坚持的术语定义及分类系统。不依从定义为12个月内缺失2次或以上治疗或监测访视(访视超过推荐日期2周以上视为缺失),不坚持定义为过去6个月内未就诊或未安排预约。相关因素分为6个维度,为评估真实世界治疗依从性提供框架。

要点

  • 不依从:12个月内缺失≥2次治疗或监测访视,访视超过推荐日期2周以上视为缺失。
  • 不坚持:过去6个月内未就诊或未安排预约。
  • 相关因素分为患者、病情、治疗、卫生系统与团队、社会/经济及其他6个维度。

核心结论

  • 建立了nAMD抗VEGF治疗不依从与不坚持的共识定义及分类系统,可用于评估不同医疗环境下的治疗依从性。

研究设计与样本

  • 系统综述现有术语后,由视网膜专家小组委员会制定定义,经改良德尔菲法由nAMD Barometer Leadership Coalition全体验证,共识标准为平均分≥7.5。
  • 随后由另一组视网膜专家背书,超过50%成员同意或强烈同意所有定义。

主要发现

  • 不依从定义为12个月内缺失2次或以上治疗或监测访视,访视超过推荐日期2周以上视为缺失。
  • 不坚持定义为过去6个月内未就诊或未安排预约。
  • 还建立了计划性终止和转诊护理术语。
  • 不依从和不坚持的原因分为6个维度:患者相关、病情相关、治疗相关、卫生系统与医疗团队相关、社会/经济及其他,并含nAMD治疗特异性子类别。

关键数值与推荐

  • 不依从:12个月内缺失≥2次治疗或监测访视;访视超过推荐日期2周以上视为缺失。
  • 不坚持:过去6个月内未就诊或未安排预约。
  • 改良德尔菲法共识标准:平均分≥7.5。
  • 第二组专家背书标准:>50%成员同意或强烈同意所有定义。

临床怎么用

  • 该分类系统可用于临床实践中标准化评估nAMD患者抗VEGF治疗的不依从和不坚持,并识别相关因素。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Poor adherence or persistence to treatment can be a barrier to optimizing clinical practice (real-world) outcomes to intravitreal injection therapy in patients with neovascular age-related macular degeneration (nAMD). Currently, there is a lack of consensus on the definition and classification of adherence specific to this context. OBJECTIVE: To describe the development and validation of terminology on patient nonadherence and nonpersistence to anti-vascular endothelial growth factor therapy. DESIGN, SETTING, AND PARTICIPANTS: Following a systematic review of currently used terminology in the literature, a subcommittee panel of retinal experts developed a set of definitions and classification for validation. Definitions were restricted to use in patients with nAMD requiring intravitreal anti-vascular endothelial growth factor therapy. Validation by the full nAMD Barometer Leadership Coalition was established using a modified Delphi approach, with predetermined mean scores of 7.5 or more signifying consensus. Subsequent endorsement of the definitions was provided from a second set of retinal experts, with more than 50% members agreeing or strongly agreeing with all definitions. MAIN OUTCOMES AND MEASURES: Development of consensus definitions for the terms adherence and persistence and a classification system for the factors associated with treatment nonadherence or nonpersistence in patients with nAMD. RESULTS: Nonadherence was defined as missing 2 or more treatment or monitoring visits over a period of 12 months, with a visit considered missed if it exceeded more than 2 weeks from the recommended date. Nonpersistence was defined by nonattendance or an appointment not scheduled within the last 6 months. The additional terms planned discontinuation and transfer of care were also established. Reasons for treatment nonadherence and nonpersistence were classified into 6 dimensions: (1) patient associated, (2) condition associated, (3) therapy associated, (4) health system and health care team associated, (5) social/economic, and (6) other, with subcategories specific to treatment for nAMD. CONCLUSIONS AND RELEVANCE: This classification system provides a framework for assessing treatment nonadherence and nonpersistence over time and across different health settings in the treatment of nAMD with current intravitreal anti-vascular endothelial growth factor treatments. This may have additional importance, given the potential association of the coronavirus pandemic on adherence to treatment in patients with nAMD.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Okada M, Wong TY, Mitchell P, et al. Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021. PMID: 34081099. doi:10.1001/jamaophthalmol.2021.1660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。